Rapamycin for Weight Loss & Metabolic Health: What the Evidence Actually Shows

Rapamycin (sirolimus, brand name Rapamune) has become one of the most talked-about drugs in longevity circles — but it is not a weight-loss drug, and it was never designed to be one. It is an FDA-approved immunosuppressant, prescribed since 1999 to prevent organ rejection in kidney transplant patients. Its reputation for extending lifespan comes almost entirely from animal studies, most famously mice fed rapamycin late in life. Human evidence is real but early: small trials measuring immune function, infection rates, and safety over about a year, not weight or lifespan. And the metabolic story has an uncomfortable twist that longevity enthusiasts often skip past — in the dosing regimen used for decades in transplant medicine, rapamycin can worsen insulin resistance and blood lipids. This article walks through what the human and animal data actually show, why the drug that extends mouse lifespan can simultaneously raise blood sugar, and how it relates (and doesn't) to proven weight-loss therapies like GLP-1 receptor agonists.

The bottom line

• Rapamycin is not FDA-approved, and has not been shown in controlled human trials, to cause weight loss. No published randomized controlled trial has weight loss as a primary or significant secondary outcome.
• Its landmark longevity result — that rapamycin fed late in life extended lifespan in genetically heterogeneous mice — is an animal finding, from the NIA Interventions Testing Program (Harrison 2009^[5]). It has never been replicated as a lifespan outcome in humans, and can't ethically be tested that way on a practical timescale.
• The human trials that exist are small, short (roughly a year or less), and measure immune function, infection rates, or safety/tolerability — not weight, and in most cases not even rapamycin itself but related "rapalog" drugs (Mannick 2014^[8]; Mannick 2018^[9]; Kraig 2018^[10]; Moel 2025^[11]).
• Chronically dosed the way transplant medicine has used it for 25+ years, rapamycin is associated with new-onset diabetes, insulin resistance, and elevated triglycerides/cholesterol — the opposite of a metabolic-health drug — because continuous exposure disrupts a second signaling complex (mTORC2) that chronic exposure doesn't need to touch (Lamming 2012^[3]; Vergès 2018^[4]).
• All weight-related, metabolic, or anti-aging use of rapamycin today is off-label. The FDA has approved sirolimus only for transplant-rejection prophylaxis and, later, for a rare lung disease (LAM) — never for obesity, metabolic disease, or aging.

How rapamycin works: mTORC1, mTORC2, and why the distinction matters

Rapamycin binds a protein called FKBP12, and together they inhibit mTOR — mechanistic target of rapamycin — the cell's central sensor for nutrients, growth signals, and energy status. Acutely inhibiting mTOR pushes cells into a catabolic, fasting-like state and switches on autophagy, the process that clears damaged proteins and organelles (Saxton 2017^[1]; Johnson 2013^[2]). That's the biological basis for interest in rapamycin as an anti-aging compound: autophagy and reduced growth-signaling are recurring themes across nearly every intervention known to extend lifespan in lab animals, from caloric restriction to genetic mTOR knockdowns.

The complication is that mTOR isn't one thing — it exists in two distinct protein complexes, mTORC1 and mTORC2. Rapamycin's primary, well-characterized target is mTORC1. But with chronic, continuous exposure, rapamycin also ends up disrupting mTORC2, a complex that's required for insulin-stimulated glucose uptake in muscle and fat tissue. That's the mechanistic root of what researchers call the rapamycin metabolic paradox: a drug that extends lifespan in mice by inhibiting mTORC1 can simultaneously cause insulin resistance by collaterally inhibiting mTORC2 (Lamming 2012^[3], animal study). A human clinical review maps the downstream consequences in transplant patients — impaired insulin signaling, β-cell dysfunction, and dyslipidemia (Vergès 2018^[4]).

Does rapamycin cause weight loss in humans? The data — and the paradox

Here is the plainest fact in this entire review: no controlled human trial has shown that rapamycin causes weight loss. That's a striking gap for a drug with this much longevity buzz, and it's worth sitting with rather than glossing over.

What human data does exist points the other direction. In kidney and other organ-transplant recipients — the population with the longest track record on chronic sirolimus, often for years at a stretch — the drug is consistently associated with new-onset diabetes after transplant, worsening insulin resistance, elevated triglycerides, and elevated LDL/total cholesterol (Vergès 2018^[4]). This isn't a rare side effect buried in a footnote; it's one of the defining metabolic trade-offs clinicians weigh when choosing sirolimus-based immunosuppression regimens.

Animal data reinforces that rapamycin is not simply mimicking caloric restriction, which reliably trims fat mass alongside its longevity effects. A dose-response mouse study found rapamycin's metabolic signature to be "distinct from dietary restriction" — the pathways rapamycin engages to extend lifespan are not the same pathways that produce leanness (Miller 2014^[6], animal study). In plain terms: a drug can extend a mouse's lifespan without making it thinner, and rapamycin appears to be exactly that kind of drug. For readers weighing genuinely evidence-backed metabolic supplements against unproven longevity compounds, our metformin vs. GLP-1 evidence review and berberine vs. GLP-1 evidence review cover agents with actual human weight and glycemic data — a useful contrast to where rapamycin's evidence currently stands.

The longevity evidence: extraordinary in mice, early in humans

Rapamycin's scientific credibility as a longevity compound rests on one of the most-replicated results in aging biology — and it is an animal result. In 2009, the NIA Interventions Testing Program reported that rapamycin, fed late in life, extended lifespan in genetically heterogeneous mice — the first pharmacologic agent shown to reproducibly extend mammalian lifespan when started in already-old animals (Harrison 2009^[5], animal study). A follow-up dose-ranging study confirmed the lifespan effect but showed it is dose- and sex-dependent, and metabolically distinct from simple calorie restriction (Miller 2014^[6], animal study). A 2021 review lays out the state of the field plainly: a large, consistent animal record, and a human evidence base that has not caught up (Selvarani 2021^[7]).

The human trials that do exist are important but modest, and none of them measure lifespan or weight. Two influential studies used rapalogs — related but distinct drugs, not rapamycin itself: everolimus in a randomized trial that improved vaccine response in elderly adults (Mannick 2014^[8]), and RTB101, with or without everolimus, in a randomized trial that reduced respiratory infections in older adults (Mannick 2018^[9]). A separate randomized trial used actual rapamycin, but its goal was narrower — establishing feasibility and safety of rapamycin treatment in an older human cohort, not measuring healthspan or weight outcomes (Kraig 2018^[10]). The most recent and largest dataset is the PEARL trial, a roughly one-year randomized trial of intermittent low-dose rapamycin in healthy adults: the drug was safe and well tolerated, with some lean-mass and pain signals reported in women — but PEARL was not designed or reported as a weight-loss study (Moel 2025^[11]).

Safety profile: from transplant medicine to off-label longevity dosing

Sirolimus has a well-established adverse-event profile from a quarter-century of transplant use: mouth and aphthous ulcers (stomatitis), increased infection risk from immunosuppression, impaired wound healing, hyperlipidemia and hypertriglyceridemia, and new-onset hyperglycemia or insulin resistance (Vergès 2018^[4]). Those are documented at the continuous, relatively high daily doses used to prevent organ rejection.

The off-label longevity community generally does not use that dosing pattern. The working hypothesis — untested at scale — is that weekly, intermittent, low-dose rapamycin might inhibit mTORC1 (the longevity-associated target) while sparing mTORC2 (the insulin-signaling complex), avoiding the metabolic harms seen in continuous transplant dosing (Lamming 2012^[3]). Early human safety data on intermittent dosing is reassuring as far as it goes — the feasibility trial found it tolerable (Kraig 2018^[10]), and PEARL's roughly one-year follow-up found no major safety signal (Moel 2025^[11]). But a year is not a lifetime, and neither trial was designed or powered to catch rare or slow-accumulating harms. Long-term human safety of intermittent low-dose rapamycin is not established — PEARL is currently the largest and longest dataset available, and it's about a year long.

Regulatory status: FDA-approved for transplant rejection, not weight loss or aging

Sirolimus was FDA-approved under the brand name Rapamune (originally Wyeth, now Pfizer) in 1999 for prophylaxis of organ rejection in kidney transplant recipients. It later received a second approval, in 2015, for lymphangioleiomyomatosis (LAM), a rare lung disease. Sirolimus-eluting coronary stents are a separate, unrelated device application of the same molecule. There is no FDA approval for sirolimus/rapamycin for weight loss, obesity, metabolic disease, or aging — in any dose, schedule, or formulation. Every use of rapamycin for those purposes today, including compounded low-dose prescriptions from longevity clinics, is off-label.

How does rapamycin compare with GLP-1 drugs like semaglutide?

It doesn't, really — the comparison is a category error, and it's worth being direct about that. GLP-1 receptor agonists like semaglutide and tirzepatide have large phase 3 randomized controlled trials in tens of thousands of participants, with weight loss of roughly 15-21% as the primary, FDA-reviewed endpoint. Rapamycin has zero weight-loss RCTs, and its best-documented human metabolic effect in the dosing regimen we have decades of data on is worsening glucose and lipid control, not improving it (Vergès 2018^[4]). The overlap between rapamycin and GLP-1 drugs is conceptual — both sit under the broader "metabolic health and longevity" umbrella that also includes agents like metformin and berberine — but that's where the similarity ends. See our metformin vs. GLP-1 and berberine vs. GLP-1 reviews for compounds with actual human weight and glycemic trial data, and our NAD vs. NMN vs. NR evidence review for another popular longevity category with a similarly early human evidence base. Combining rapamycin with a GLP-1 drug is a idea circulating in some longevity communities, but it is entirely speculative and has not been studied in humans — it should not be presented, or pursued, as an evidence-backed protocol.

How to read this research